Equillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UC [Seeking Alpha]
Equillium, Inc. (EQ)
Last equillium, inc. earnings: 3/26 04:07 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
A phase 1 proof-of-concept study for EQ504 in ulcerative colitis is set to begin in mid-2026, with early data expected within six months afterwards. EQ504's mechanism is validated by Tapinarof's approval in skin disorders, supporting its potential in both gastrointestinal and lung indications; Along with POC of anti-inflammatory cytokines IL-10 and IL-22. The global ulcerative colitis treatment market is expected to grow to $15.81 billion by 2034. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Lacheev/iStock via Getty Images Equillium, Inc. NASDAQ: EQ ) is a very interesting biotech because it is in the process of developing its drug EQ504 for the treatment of patients with ulcerative colitis [UC]. A recent event that happened is that This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketpla
Show less
Read more
Impact Snapshot
Event Time:
EQ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EQ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EQ alerts
High impacting Equillium, Inc. news events
Weekly update
A roundup of the hottest topics
EQ
News
- Equillium (EQ) had its "buy" rating reaffirmed by Roth Mkm. They now have a $12.00 price target on the stock.MarketBeat
- Equillium (EQ) is now covered by B. Riley Financial, Inc.. They set a "buy" rating and a $6.00 price target on the stock.MarketBeat
- Equillium (EQ) was given a new $6.00 price target by Raymond James Financial, Inc.. They now have a "strong-buy" rating on the stock.MarketBeat
- Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of ImmunologistsGlobeNewswire
- Equillium (EQ) is now covered by Cantor Fitzgerald. They set an "overweight" rating and a $10.00 price target on the stock.MarketBeat
EQ
Sec Filings
- 4/17/26 - Form EFFECT
- 4/15/26 - Form ARS
- 4/15/26 - Form DEFA14A
- EQ's page on the SEC website